Featured Research

from universities, journals, and other organizations

Arsenic Aids Tumor Imaging When Joined To Cancer-homing Drug, Researchers Find

Date:
March 5, 2008
Source:
UT Southwestern Medical Center
Summary:
Arsenic linked to a drug that binds to the blood vessels of cancerous tumors provides a powerful imaging agent that could one day allow physicians to detect hard-to-find tumors and more closely monitor cancer's response to therapy.

Drs. Philip Thorpe (left) , professor of pharmacology, and Ralph Mason, professor of radiology, have shown in animals that arsenic linked to a drug that binds to the blood vessels of cancerous tumors provides a powerful imaging agent.
Credit: Image courtesy of UT Southwestern Medical Center

Arsenic linked to a drug that binds to the blood vessels of cancerous tumors provides a powerful imaging agent that could one day allow physicians to detect hard-to-find tumors and more closely monitor cancer's response to therapy, researchers at UT Southwestern Medical Center have found.

The findings, based on animal studies and appearing in the journal Clinical Cancer Research, mark the first time arsenic has been used to label antibodies for the detection of tumors.

Dr. Philip Thorpe, professor of pharmacology at UT Southwestern and senior author of the study, helped create the cancer drug called bavituximab, an antibody that homes in on a specific molecular target on the blood vessels that feed tumors. Bavituximab is being tested in clinical trials to treat solid-tumor cancers in combination with chemotherapy.

"While arsenic has been used as a poison for centuries, the dose of arsenic needed for imaging tumors is about one-millionth of that needed to cause toxicity," Dr. Thorpe said.

"Arsenic-labeled bavituximab appears to be safe."

In the study, Dr. Thorpe and his colleagues injected radioarsenic-labeled bavituximab into rats with prostate tumors. When the bavituximab bound to its target on the the tumor blood vessels, the tag-along arsenic created a "hot spot" that researchers then imaged using positron emission tomography methods. The radioactivity levels produced by the arsenic are comparable to those used in standard, routine imaging procedures in humans. The technique allowed them to locate and capture unusually clear images of the tumors. They also discovered that there was little or no detectable uptake of bavituximab by normal organs, including the liver, a common site where drugs become entrapped.

"We hope to use this technique to detect early tumor deposits that are not visible using other imaging techniques," said Dr. Thorpe. "The images we obtain are so clear that we may be able to see secondary tumors that have spread from the original tumor mass and lodged in distant organs."

The forms of arsenic used in the experiments are called radionuclides, which are radioactive versions, or isotopes, of the element. Several radionuclides currently are used in imaging, but many of the isotopes decay, or breakdown, before they reach the target in the body. The slow rate of decay of arsenic isotopes, together with their stable chemistry, allowed the researchers to couple arsenic to bavituximab and obtain images of the tumors for several days after the drug was given. Optimal tumor imaging in humans is often achieved three days or more after a radio-labeled antibody is administered.

"Long neglected as an awkward Cinderella, arsenic has great potential for new imaging agents and therapeutics based on multiple isotopes with diverse useful characteristics," said Dr. Ralph Mason, professor of radiology, director of the UT Southwestern Cancer Imaging Program and one of the study's authors.

Dr. Mason recently received a grant from the Department of Defense Breast Cancer Initiative to investigate whether arsenic could be used to image breast tumors.

In addition to Drs. Thorpe and Mason, other investigators in UT Southwestern's Harold C. Simmons Comprehensive Cancer Center carried out the research in collaboration with colleagues from UT Austin, Johannes Gutenberg University of Mainz in Germany and the University of Brussels in Belgium. The collaboration included pharmacologists, physicists and chemists.

Other UT Southwestern scientists involved in the study were Dr. Matthew Lewis, assistant professor of radiology; Dr. Dawen Zhao, assistant professor of radiology; Dr. Edward Tsyganov, clinical assistant professor of radiology; Dr. Nikolai Slavine, assistant professor of radiology; Linda Watkins, research scientist in pharmacology; Dr. Vikram Kodibagkar, assistant professor of radiology; and Dr. Peter Antich, professor of radiology.

The research was funded by Gillson Longenbaugh Foundation, National Cancer Institute, Peregrine Pharmaceuticals Inc., Deutsche Forschungsgemeinschaft and the Department of Defense.

Peregrine has exclusively licensed bavituximab from UT Southwestern and has a sponsored research agreement to further explore clinical uses of the drug. Dr. Thorpe is a consultant to and has an equity interest in the company.


Story Source:

The above story is based on materials provided by UT Southwestern Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

UT Southwestern Medical Center. "Arsenic Aids Tumor Imaging When Joined To Cancer-homing Drug, Researchers Find." ScienceDaily. ScienceDaily, 5 March 2008. <www.sciencedaily.com/releases/2008/03/080301214730.htm>.
UT Southwestern Medical Center. (2008, March 5). Arsenic Aids Tumor Imaging When Joined To Cancer-homing Drug, Researchers Find. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2008/03/080301214730.htm
UT Southwestern Medical Center. "Arsenic Aids Tumor Imaging When Joined To Cancer-homing Drug, Researchers Find." ScienceDaily. www.sciencedaily.com/releases/2008/03/080301214730.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins